Findings
Standard assessments lack sensitivity in early stages of neurodegenerative diseases.
Challenges with the validity and quality of RMT measurements.
Issues related to equity and inclusion in deploying digital tools.
Importance of considering feasibility, acceptance, usability, and ecological validity of digital endpoints.

Recommendations
Develop regulatory strategies early on.
Ensure equity and inclusion in deploying digital tools.
Address challenges related to the validity and usability of digital endpoints.
Promote public-private partnerships to address privacy and security concerns.
Involve patients and stakeholders in the design and implementation of digital tools.

Regulatory Considerations
Acceptance of digital endpoints by regulatory authorities is crucial.
Validation with current gold standards and clinically meaningful legacy endpoints.
Ensure data security and privacy.